var data={"title":"Anesthesia for noncardiac surgery in patients with ischemic heart disease","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Anesthesia for noncardiac surgery in patients with ischemic heart disease</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/contributors\" class=\"contributor contributor_credentials\">Nadia Blakemore Hensley, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/contributors\" class=\"contributor contributor_credentials\">Charles W Hogue, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/contributors\" class=\"contributor contributor_credentials\">Jonathan B Mark, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/contributors\" class=\"contributor contributor_credentials\">Nancy A Nussmeier, MD, FAHA</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 20, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H353771159\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with ischemic heart disease undergoing noncardiac surgery are at increased risk for perioperative cardiovascular events, such as myocardial infarction, heart failure, and mortality. Those with recent myocardial infarction or unstable angina are at very high risk if they require urgent or emergency surgery.</p><p>This topic will review the preanesthesia consultation, anesthetic care, and immediate postoperative management of patients with ischemic heart disease having elective, urgent, or emergency noncardiac surgery. Anesthetic management of patients with ischemic and nonischemic heart failure is discussed in detail separately (see <a href=\"topic.htm?path=anesthesia-for-noncardiac-surgery-in-patients-with-heart-failure\" class=\"medical medical_review\">&quot;Anesthesia for noncardiac surgery in patients with heart failure&quot;</a>). Preoperative medical evaluation and management of patients with known or suspected ischemic heart disease is addressed elsewhere. (See <a href=\"topic.htm?path=evaluation-of-cardiac-risk-prior-to-noncardiac-surgery\" class=\"medical medical_review\">&quot;Evaluation of cardiac risk prior to noncardiac surgery&quot;</a> and <a href=\"topic.htm?path=management-of-cardiac-risk-for-noncardiac-surgery\" class=\"medical medical_review\">&quot;Management of cardiac risk for noncardiac surgery&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H132216151\"><span class=\"h1\">PREANESTHESIA CONSULTATION</span></p><p class=\"headingAnchor\" id=\"H132216315\"><span class=\"h2\">Evaluation and management of high cardiac risk</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All patients with ischemic heart disease are assessed for risk of myocardial injury after noncardiac surgery (MINS) [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/1,2\" class=\"abstract_t\">1,2</a>]. (See <a href=\"topic.htm?path=evaluation-of-cardiac-risk-prior-to-noncardiac-surgery\" class=\"medical medical_review\">&quot;Evaluation of cardiac risk prior to noncardiac surgery&quot;</a> and <a href=\"topic.htm?path=management-of-cardiac-risk-for-noncardiac-surgery\" class=\"medical medical_review\">&quot;Management of cardiac risk for noncardiac surgery&quot;</a>.)</p><p>Risk is related to individual patient factors as well as the type of surgical procedure, as discussed in detail separately (<a href=\"image.htm?imageKey=CARD%2F57075\" class=\"graphic graphic_table graphicRef57075 \">table 1</a> and <a href=\"image.htm?imageKey=CARD%2F96563\" class=\"graphic graphic_algorithm graphicRef96563 \">algorithm 1</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Recent myocardial infarction or unstable angina</strong> &ndash; Patients with recent (&lt;60 days) myocardial infarction (MI) or unstable angina are at very high risk for major cardiovascular outcome. Evaluation and management are discussed in separate topics. (See <a href=\"topic.htm?path=evaluation-of-cardiac-risk-prior-to-noncardiac-surgery#H418242309\" class=\"medical medical_review\">&quot;Evaluation of cardiac risk prior to noncardiac surgery&quot;, section on 'Very high-risk patients'</a> and <a href=\"topic.htm?path=management-of-cardiac-risk-for-noncardiac-surgery#H234441526\" class=\"medical medical_review\">&quot;Management of cardiac risk for noncardiac surgery&quot;, section on 'Patients with a recent acute coronary syndrome'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Recent percutaneous coronary intervention</strong> &ndash; Patients with coronary stents undergoing noncardiac surgery are at high risk for adverse cardiovascular outcome even when receiving perioperative antiplatelet therapy, and are also at high risk for major bleeding events [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/3\" class=\"abstract_t\">3</a>]. Our approach to the perioperative management of patients receiving dual antiplatelet therapy after percutaneous coronary intervention (PCI) is discussed separately. (See <a href=\"topic.htm?path=noncardiac-surgery-after-percutaneous-coronary-intervention#H350963316\" class=\"medical medical_review\">&quot;Noncardiac surgery after percutaneous coronary intervention&quot;, section on 'Our approach'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Urgent or emergency surgery </strong>&ndash; If urgent or emergency surgery is necessary in a patient with ischemic heart disease, urgent consultation with a cardiologist is useful in decision-making regarding management strategies. (See <a href=\"topic.htm?path=management-of-cardiac-risk-for-noncardiac-surgery#H234441628\" class=\"medical medical_review\">&quot;Management of cardiac risk for noncardiac surgery&quot;, section on 'Patients who need urgent or emergent surgery'</a>.)</p><p/><p class=\"bulletIndent1\">If extremely urgent or emergency surgery is performed after recent administration of antiplatelet drugs, platelet transfusion may be necessary if excessive bleeding occurs during or after surgery. However, we do not order or administer platelets on a prophylactic basis. (See <a href=\"topic.htm?path=congenital-and-acquired-disorders-of-platelet-function#H38\" class=\"medical medical_review\">&quot;Congenital and acquired disorders of platelet function&quot;, section on 'Platelet transfusion'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>High-risk surgical procedure</strong> &ndash; Classic surgical risk categories for perioperative major adverse cardiovascular events, defined as cardiac death or acute MI, were typically categorized as high (&gt;5 percent), intermediate (1 to 5 percent), or low (&lt;1 percent) risk (<a href=\"image.htm?imageKey=CARD%2F57828\" class=\"graphic graphic_table graphicRef57828 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/4\" class=\"abstract_t\">4</a>]. However, a continuum of risk exists within these categories (<a href=\"image.htm?imageKey=ANEST%2F116645\" class=\"graphic graphic_table graphicRef116645 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"topic.htm?path=preanesthesia-evaluation-for-noncardiac-surgery#H2810882344\" class=\"medical medical_review\">&quot;Preanesthesia evaluation for noncardiac surgery&quot;, section on 'Surgical risk'</a> and <a href=\"topic.htm?path=perioperative-myocardial-infarction-or-injury-after-noncardiac-surgery#H3\" class=\"medical medical_review\">&quot;Perioperative myocardial infarction or injury after noncardiac surgery&quot;, section on 'Predictors'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H18794857\"><span class=\"h2\">Preoperative medication management</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Beta blockers</strong> &ndash; Patients with ischemic heart disease who are already taking beta blockers should continue taking their regular dose, including the morning of surgery and throughout the perioperative period, in order to minimize tachycardia or ischemia [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Beta blockers are not initiated prophylactically unless recommended by a consulting cardiologist based on strong indications. Further discussion is available in another topic. (See <a href=\"topic.htm?path=management-of-cardiac-risk-for-noncardiac-surgery#H17\" class=\"medical medical_review\">&quot;Management of cardiac risk for noncardiac surgery&quot;, section on 'Beta blockers'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Statins</strong> &ndash; Patients taking statins should continue this therapy throughout the perioperative period. A consultant cardiologist may recommend initiation of statin therapy in previously untreated patients [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/1,2\" class=\"abstract_t\">1,2</a>]. (See <a href=\"topic.htm?path=management-of-cardiac-risk-for-noncardiac-surgery#H33\" class=\"medical medical_review\">&quot;Management of cardiac risk for noncardiac surgery&quot;, section on 'Statins'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">Aspirin</a> &ndash; For most patients taking aspirin for primary or secondary prevention of cardiovascular disease, the dose is held for five to seven days before noncardiac surgery [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/6\" class=\"abstract_t\">6</a>]. Aspirin is restarted after surgery, when the perioperative risk of major bleeding has passed. (See <a href=\"topic.htm?path=management-of-cardiac-risk-for-noncardiac-surgery#H147659010\" class=\"medical medical_review\">&quot;Management of cardiac risk for noncardiac surgery&quot;, section on 'Antiplatelet therapy'</a>.)</p><p/><p class=\"bulletIndent1\">The approach to perioperative <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> administration is different for certain types of surgery (eg, carotid, peripheral vascular, or cardiac surgery) and in patients receiving dual antiplatelet therapy (aspirin plus a P2Y<sub>12</sub> receptor blocker, such as <a href=\"topic.htm?path=clopidogrel-drug-information\" class=\"drug drug_general\">clopidogrel</a>, <a href=\"topic.htm?path=prasugrel-drug-information\" class=\"drug drug_general\">prasugrel</a>, or <a href=\"topic.htm?path=ticagrelor-drug-information\" class=\"drug drug_general\">ticagrelor</a>) after PCI.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Carotid surgery (see <a href=\"topic.htm?path=carotid-endarterectomy#H93838520\" class=\"medical medical_review\">&quot;Carotid endarterectomy&quot;, section on 'Antiplatelet therapy'</a>)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Peripheral vascular surgery (see <a href=\"topic.htm?path=treatment-of-chronic-limb-threatening-ischemia#H519589654\" class=\"medical medical_review\">&quot;Treatment of chronic limb-threatening ischemia&quot;, section on 'Antithrombotic therapy'</a>)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Cardiac surgery (see <a href=\"topic.htm?path=medical-therapy-to-prevent-complications-after-coronary-artery-bypass-graft-surgery#H2\" class=\"medical medical_review\">&quot;Medical therapy to prevent complications after coronary artery bypass graft surgery&quot;, section on 'Aspirin'</a>)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>PCI (see <a href=\"topic.htm?path=noncardiac-surgery-after-percutaneous-coronary-intervention#H350963316\" class=\"medical medical_review\">&quot;Noncardiac surgery after percutaneous coronary intervention&quot;, section on 'Our approach'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers </strong>&ndash; Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are typically continued in the perioperative period, particularly for patients with coexisting heart failure [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/1,2,7\" class=\"abstract_t\">1,2,7</a>]. Since these agents may cause perioperative hypotension, some clinicians administer the evening dose of an ACE inhibitor or ARB on the day before surgery but hold the morning dose on the day of surgery if large perioperative fluid shifts are anticipated [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/8,9\" class=\"abstract_t\">8,9</a>]. ACE inhibitors and ARBs are always held in patients with hemodynamic instability, hypovolemia, or acute elevation of creatinine. Further discussion is available in another topic. (See <a href=\"topic.htm?path=perioperative-management-of-heart-failure-in-patients-undergoing-noncardiac-surgery#H694557405\" class=\"medical medical_review\">&quot;Perioperative management of heart failure in patients undergoing noncardiac surgery&quot;, section on 'ACE inhibitors and angiotensin receptor blockers'</a> and <a href=\"topic.htm?path=perioperative-medication-management#H7\" class=\"medical medical_review\">&quot;Perioperative medication management&quot;, section on 'ACE inhibitors and angiotensin II receptor blockers'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=clonidine-drug-information\" class=\"drug drug_general\">Clonidine</a> &ndash; Clonidine is continued if it has been chronically administered, since rebound hypertension may occur with abrupt withdrawal. (See <a href=\"topic.htm?path=management-of-cardiac-risk-for-noncardiac-surgery#H147659083\" class=\"medical medical_review\">&quot;Management of cardiac risk for noncardiac surgery&quot;, section on 'Clonidine'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Other cardiovascular medications</strong> &ndash; We continue most other chronically administered cardiovascular medications (eg, calcium channel blockers, <a href=\"topic.htm?path=digoxin-drug-information\" class=\"drug drug_general\">digoxin</a>, and diuretics) in the perioperative period; specific details are discussed separately. (See <a href=\"topic.htm?path=perioperative-medication-management#H3\" class=\"medical medical_review\">&quot;Perioperative medication management&quot;, section on 'Cardiovascular medications'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H117881487\"><span class=\"h2\">Laboratory</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Preoperative screening for MINS is performed in patients with high cardiac risk (<a href=\"image.htm?imageKey=CARD%2F57075\" class=\"graphic graphic_table graphicRef57075 \">table 1</a>); this includes a cardiac troponin level obtained at baseline, as discussed separately. (See <a href=\"topic.htm?path=evaluation-of-cardiac-risk-prior-to-noncardiac-surgery#H189447240\" class=\"medical medical_review\">&quot;Evaluation of cardiac risk prior to noncardiac surgery&quot;, section on 'Troponin and brain natriuretic peptide'</a> and <a href=\"topic.htm?path=perioperative-myocardial-infarction-or-injury-after-noncardiac-surgery#H378922\" class=\"medical medical_review\">&quot;Perioperative myocardial infarction or injury after noncardiac surgery&quot;, section on 'Troponin'</a>.) </p><p>Other criteria for ordering preoperative blood tests are the same for patients with ischemic heart disease as for other patients undergoing noncardiac surgery. It is reasonable to obtain a metabolic panel (sodium, potassium, chloride, carbon dioxide, glucose, blood urea nitrogen, creatinine) in patients receiving diuretic therapy chronically and in patients with renal insufficiency.</p><p class=\"headingAnchor\" id=\"H128997740\"><span class=\"h2\">Electrocardiogram</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A preoperative baseline resting 12-lead electrocardiogram (ECG) is obtained for all patients with symptoms of myocardial ischemia and for asymptomatic patients at high risk for MINS (<a href=\"image.htm?imageKey=CARD%2F57075\" class=\"graphic graphic_table graphicRef57075 \">table 1</a>), particularly if a high-risk surgical procedure is planned (<a href=\"image.htm?imageKey=CARD%2F57828\" class=\"graphic graphic_table graphicRef57828 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/1,2\" class=\"abstract_t\">1,2</a>]. A baseline ECG is useful when the postoperative ECG is abnormal. (See <a href=\"topic.htm?path=evaluation-of-cardiac-risk-prior-to-noncardiac-surgery#H2\" class=\"medical medical_review\">&quot;Evaluation of cardiac risk prior to noncardiac surgery&quot;, section on 'Initial preoperative evaluation'</a>.) </p><p class=\"headingAnchor\" id=\"H128998269\"><span class=\"h2\">Management of implantable cardioverter defibrillators and pacemakers</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with ischemic heart disease or ischemic cardiomyopathy may have a single- or dual-chamber pacemaker, biventricular pacemaker, <span class=\"nowrap\">and/or</span> an implantable cardioverter defibrillator device (ICD) [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/10\" class=\"abstract_t\">10</a>]. Perioperative management of ICDs and pacemakers is discussed elsewhere [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/11,12\" class=\"abstract_t\">11,12</a>]. (See <a href=\"topic.htm?path=pacing-system-malfunction-evaluation-and-management#H27\" class=\"medical medical_review\">&quot;Pacing system malfunction: Evaluation and management&quot;, section on 'Electromagnetic interference'</a> and <a href=\"topic.htm?path=perioperative-management-of-patients-with-a-pacemaker-or-implantable-cardioverter-defibrillator\" class=\"medical medical_review\">&quot;Perioperative management of patients with a pacemaker or implantable cardioverter-defibrillator&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H132216170\"><span class=\"h1\">ANESTHETIC GOALS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Anesthetic goals in patients with ischemic heart disease are prevention, detection, and treatment of myocardial ischemia.</p><p class=\"headingAnchor\" id=\"H213850611\"><span class=\"h2\">Prevention of ischemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following hemodynamic and physiologic goals optimize myocardial oxygen (O<sub>2</sub>) supply and minimize myocardial O<sub>2</sub> demand, regardless of the surgical procedure or the anesthetic techniques and agents selected (<a href=\"image.htm?imageKey=ANEST%2F91907\" class=\"graphic graphic_table graphicRef91907 \">table 4</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Low to normal heart rate</strong> &ndash; Maintain low to normal heart rate (HR) (eg, 50 to 80 <span class=\"nowrap\">beats/minute</span> [bpm]) [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/13\" class=\"abstract_t\">13</a>]. Tachycardia compromises both oxygen supply and demand.</p><p/><p class=\"bulletIndent1\">Myocardial oxygen supply is affected by the duration of diastole because 70 to 80 percent of coronary blood flow occurs during diastole. Also, myocardial O<sub>2</sub> demand more than doubles when HR doubles [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/14\" class=\"abstract_t\">14</a>]. The relationship between HR and the duration of diastole is nonlinear (<a href=\"image.htm?imageKey=ANEST%2F94174\" class=\"graphic graphic_figure graphicRef94174 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/15,16\" class=\"abstract_t\">15,16</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Normal to high blood pressure</strong> &ndash; Maintain blood pressure (BP) within 20 percent of baseline. Typically, we aim for a mean arterial BP 75 to 95 mmHg <span class=\"nowrap\">and/or</span> diastolic BP 65 to 85 mmHg to maintain coronary perfusion pressure. Severe hypotension reduces myocardial oxygen supply, while severe hypertension increases demand. </p><p/><p class=\"bulletIndent1\">Prompt treatment of arterial hypotension is warranted to avoid supply-mediated ischemia. However, hypertension may cause demand-mediated ischemia by increasing systolic wall stress and left ventricular end-diastolic pressure (LVEDP) (<a href=\"image.htm?imageKey=ANEST%2F91907\" class=\"graphic graphic_table graphicRef91907 \">table 4</a>). The subendocardium is particularly vulnerable to ischemia because the compressive effect of increases in LVEDP becomes the limiting factor for subendocardial coronary blood flow.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Normal left ventricular end-diastolic volume</strong> &ndash; Avoid left ventricular (LV) distention caused by fluid overload, as this may increase systolic wall stress and myocardial O<sub>2</sub> demand. Although central venous pressure or pulmonary artery pressures are used as surrogates to estimate LV volume, these measurements have limitations [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/17-19\" class=\"abstract_t\">17-19</a>]. (See <a href=\"#H295569606\" class=\"local\">'Monitoring for ischemia'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Adequate arterial oxygen content </strong>&ndash; Maintain normal to high hemoglobin saturation (measured with pulse oximetry) <span class=\"nowrap\">and/or</span> arterial PaO<sub>2</sub> (measured with arterial blood gases), and maintain adequate hemoglobin (Hgb) levels (&ge;8 <span class=\"nowrap\">g/dL)</span> to maximize O<sub>2</sub> content in coronary arterial blood. (See <a href=\"topic.htm?path=indications-and-hemoglobin-thresholds-for-red-blood-cell-transfusion-in-the-adult#H606955\" class=\"medical medical_review\">&quot;Indications and hemoglobin thresholds for red blood cell transfusion in the adult&quot;, section on 'Cardiovascular disease'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Normothermia</strong> &ndash; Avoid hypothermia and maintain normothermia during and after surgery. Normothermia favors tissue release of oxygen. Adverse consequences of hypothermia include shivering, which increases myocardial oxygen demand and may result in myocardial ischemia.</p><p/><p class=\"headingAnchor\" id=\"H295569606\"><span class=\"h2\">Monitoring for ischemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although myocardial ischemia is possible without any changes in systemic hemodynamics, monitoring for imbalances in myocardial oxygen supply versus demand, as well as for development of ischemia, is continuous throughout the perioperative period.</p><p>Cardiovascular monitoring in patients with ischemic heart disease includes the following [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/20\" class=\"abstract_t\">20</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Electrocardiography</strong> &ndash; All patients have continuous electrocardiography (ECG) monitoring to detect myocardial ischemia <span class=\"nowrap\">and/or</span> arrhythmias.</p><p/><p class=\"bulletIndent1\">Computerized ST-segment trending is superior to visual clinical interpretation in the identification of ST-segment changes [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/21-24\" class=\"abstract_t\">21-24</a>], and multiple-lead monitoring is more sensitive than single-lead monitoring. Although ECG is a relatively insensitive method for intraoperative detection of myocardial ischemia [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/20,25\" class=\"abstract_t\">20,25</a>], leads II and V<sub>5</sub> detected 80 percent of all episodes detected by a 12-lead ECG in one study [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/25\" class=\"abstract_t\">25</a>], while another study suggested that lead V<sub>4</sub> may be even more sensitive [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/26\" class=\"abstract_t\">26</a>].</p><p/><p class=\"bulletIndent1\">Despite limitations in sensitivity of ECG monitoring, intraoperative and postoperative ST-segment changes are associated with cardiac morbidity and mortality after noncardiac surgery in patients at high risk for myocardial ischemia [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/1\" class=\"abstract_t\">1</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Intra-arterial catheter</strong> &ndash;<strong> </strong>Invasive measurement of arterial BP is employed when moment-to-moment BP changes are anticipated during the surgical procedure and rapid detection is vital. These conditions apply to patients with severe coronary artery disease, cardiomyopathy, or hemodynamic instability, as well as to patients with stable ischemic heart disease who are undergoing a major procedure that is likely to cause rapid blood loss or large fluid shifts. Direct arterial BP monitoring is superior to indirect monitoring techniques for the early detection of intraoperative hypotension [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/27\" class=\"abstract_t\">27</a>]. Ideally, the intra-arterial catheter is inserted prior to induction of anesthesia.</p><p/><p class=\"bulletIndent1\">In addition, an intra-arterial catheter is useful to guide management of vasoactive drugs and facilitate sampling of arterial blood for measurements of blood gases and other laboratory values throughout the perioperative period.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Central venous catheter</strong> &ndash;<strong> </strong>The decision to place a central venous catheter (CVC) is based on the surgical potential for significant blood loss <span class=\"nowrap\">and/or</span> large fluid shifts, as well as the likelihood of administration of continuous infusions of vasoactive drugs. Measurement of central venous pressure (CVP) may provide supplemental data regarding intravascular volume status, although CVP is a poor predictor of fluid responsiveness [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/18,28,29\" class=\"abstract_t\">18,28,29</a>]. (See <a href=\"topic.htm?path=intraoperative-fluid-management#H1307207319\" class=\"medical medical_review\">&quot;Intraoperative fluid management&quot;, section on 'Static (traditional) parameters'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pulmonary artery catheter </strong>&ndash; We do not recommend inserting a pulmonary artery catheter (PAC) for detection of myocardial ischemia [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Intraoperative changes in pulmonary artery pressure, specifically wedge pressure, are poor predictors of myocardial ischemia compared with ECG or transesophageal echocardiographic monitoring [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/30\" class=\"abstract_t\">30</a>]. Furthermore, there appears to be no benefit and possible harm from perioperative PAC use in most patients undergoing either cardiac or noncardiac surgery [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/19,31-33\" class=\"abstract_t\">19,31-33</a>].</p><p/><p class=\"bulletIndent1\">In a few selected patients with severe cardiovascular conditions significantly affecting hemodynamics, PAC insertion may be reasonable to monitor filling pressures, determine cardiac output, or follow trends in pulmonary arterial pressures (PAP). The decision is based upon both the significance of the cardiovascular condition (eg, severe cardiomyopathy or valvular lesions) and the risks of the planned surgical procedure (eg, the potential for significant fluid shifts and bleeding). (See <a href=\"topic.htm?path=pulmonary-artery-catheterization-indications-contraindications-and-complications-in-adults\" class=\"medical medical_review\">&quot;Pulmonary artery catheterization: Indications, contraindications, and complications in adults&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Transesophageal echocardiography </strong>&ndash;<strong> </strong>Continuous intraoperative transesophageal echocardiography (TEE) monitoring may be useful to detect new regional wall motion abnormalities in patients at high risk, particularly those undergoing major surgery [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/20\" class=\"abstract_t\">20</a>]. TEE monitoring has higher sensitivity for detecting myocardial ischemia than ECG or PAC monitoring [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/34-38\" class=\"abstract_t\">34-38</a>]. However, there are no data demonstrating that TEE monitoring can decrease the incidence of adverse perioperative cardiovascular events [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/1,39,40\" class=\"abstract_t\">1,39,40</a>]. (See <a href=\"topic.htm?path=intraoperative-transesophageal-echocardiography-for-noncardiac-surgery\" class=\"medical medical_review\">&quot;Intraoperative transesophageal echocardiography for noncardiac surgery&quot;</a>.)</p><p/><p class=\"bulletIndent1\">Emergency use of intraoperative or perioperative TEE is indicated to determine the cause of any unexplained persistent or life-threatening circulatory instability (&quot;rescue echo&quot;), if equipment and expertise are available [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/41\" class=\"abstract_t\">41</a>]. TEE may identify hypovolemia, left <span class=\"nowrap\">and/or</span> right ventricular dysfunction, pericardial effusion or tamponade, valvular stenosis or regurgitation, intrapulmonary emboli, or left ventricular outflow tract obstruction [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/41\" class=\"abstract_t\">41</a>]. (See <a href=\"topic.htm?path=intraoperative-rescue-transesophageal-echocardiography-tee\" class=\"medical medical_review\">&quot;Intraoperative rescue transesophageal echocardiography (TEE)&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H319624669\"><span class=\"h2\">Treatment of ischemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The decision to treat intraoperative myocardial ischemia is typically based on observing characteristic ST-segment changes on the ECG, most commonly new horizontal or downsloping ST-segment depressions. In such patients, treatment of tachycardia is usually the first step. If ischemic ECG changes persist, administration of <a href=\"topic.htm?path=nitroglycerin-glyceryl-trinitrate-drug-information\" class=\"drug drug_general\">nitroglycerin</a> is often effective; if necessary, nitroglycerin is coadministered with <a href=\"topic.htm?path=phenylephrine-drug-information\" class=\"drug drug_general\">phenylephrine</a> titrated to maintain normal arterial BP [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/42,43\" class=\"abstract_t\">42,43</a>].</p><p>The following interventions optimize myocardial oxygen supply and minimize myocardial oxygen demand in patients who develop intraoperative myocardial ischemia:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Treat tachycardia </strong>&ndash; Intraoperative tachycardia (or even heart rate [HR] exceeding 80 bpm) caused by pain or inadequate anesthesia is treated immediately by administering a dose of an intravenous anesthetic (eg, <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>) or an opiate, or by deepening an inhaled general anesthetic. If an epidural catheter is in place, an additional dose of local anesthetic can be provided to deepen anesthesia. If these measures are not effective in decreasing HR, an intravenous beta blocker (eg, <a href=\"topic.htm?path=esmolol-drug-information\" class=\"drug drug_general\">esmolol</a>, <a href=\"topic.htm?path=metoprolol-drug-information\" class=\"drug drug_general\">metoprolol</a>, or <a href=\"topic.htm?path=labetalol-drug-information\" class=\"drug drug_general\">labetalol</a>) is administered, whether or not there is evidence of ischemia.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Treat hypertension</strong> &ndash; Increases in BP caused by pain or inadequate anesthesia are treated immediately by administering a dose of an intravenous anesthetic (eg, <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>) or an opiate, by deepening general anesthesia with an inhaled anesthetic, or by administering additional local anesthetic through an epidural catheter. Administration of an intravenous beta blocker (eg, <a href=\"topic.htm?path=esmolol-drug-information\" class=\"drug drug_general\">esmolol</a>, <a href=\"topic.htm?path=metoprolol-drug-information\" class=\"drug drug_general\">metoprolol</a>, or <a href=\"topic.htm?path=labetalol-drug-information\" class=\"drug drug_general\">labetalol</a>) <span class=\"nowrap\">and/or</span> a vasodilating agent (eg, labetalol, <a href=\"topic.htm?path=nicardipine-drug-information\" class=\"drug drug_general\">nicardipine</a>, or <a href=\"topic.htm?path=nitroglycerin-glyceryl-trinitrate-drug-information\" class=\"drug drug_general\">nitroglycerin</a>) may also be necessary.</p><p/><p class=\"bulletIndent1\">For hypertensive patients who develop persistent myocardial ischemia during the intraoperative period, an intravenous <a href=\"topic.htm?path=nitroglycerin-glyceryl-trinitrate-drug-information\" class=\"drug drug_general\">nitroglycerin</a> infusion is titrated (at 10 to 400 <span class=\"nowrap\">mcg/minute;</span> 0.1 to 4 <span class=\"nowrap\">mcg/kg/minute)</span> to control BP (<a href=\"image.htm?imageKey=ANEST%2F96387\" class=\"graphic graphic_table graphicRef96387 \">table 5</a>). Nitroglycerin causes coronary arterial vasodilation of the large epicardial conductance vessels and decreases left ventricular (LV) preload due to venodilation. These benefits must be weighed against the risk of hypotension and dose-related reflex tachycardia. The additive vasodilatory effects of certain anesthetic agents and nitroglycerin may lead to significant hypotension and worsening myocardial ischemia. Thus, addition of a <a href=\"topic.htm?path=phenylephrine-drug-information\" class=\"drug drug_general\">phenylephrine</a> infusion (at 10 to 200 <span class=\"nowrap\">mcg/minute;</span> 0.1 to 2 <span class=\"nowrap\">mcg/kg/minute)</span> may be necessary to maintain adequate BP (<a href=\"image.htm?imageKey=ANEST%2F96387\" class=\"graphic graphic_table graphicRef96387 \">table 5</a>). An intra-arterial catheter for continuous BP monitoring is desirable during titration of a continuous infusion of nitroglycerin.</p><p/><p class=\"bulletIndent1\">Prophylactic intravenous <a href=\"topic.htm?path=nitroglycerin-glyceryl-trinitrate-drug-information\" class=\"drug drug_general\">nitroglycerin</a> is not administered, as it is not effective in reducing myocardial ischemia in patients undergoing noncardiac surgery [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/1,2,44\" class=\"abstract_t\">1,2,44</a>]. We avoid transdermal nitroglycerin because absorption may be uneven. (See <a href=\"topic.htm?path=management-of-cardiac-risk-for-noncardiac-surgery#H34\" class=\"medical medical_review\">&quot;Management of cardiac risk for noncardiac surgery&quot;, section on 'Nitrate therapy'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Treat hypotension</strong> &ndash; Decreases in BP (eg, mean arterial BP &lt;75 mmHg or diastolic BP &lt;65 mmHg) may be initially managed by reducing excessive anesthetic depth and giving intravenous fluid (see <a href=\"topic.htm?path=intraoperative-fluid-management\" class=\"medical medical_review\">&quot;Intraoperative fluid management&quot;</a>). Significant hypotension is corrected by administering an alpha<sub>1</sub> receptor agonist (eg, <a href=\"topic.htm?path=phenylephrine-drug-information\" class=\"drug drug_general\">phenylephrine</a> 40 to 100 mcg) <span class=\"nowrap\">and/or</span> a <span class=\"nowrap\">direct/indirect</span> sympathomimetic with beta and alpha agonist effects (eg, <a href=\"topic.htm?path=ephedrine-systemic-drug-information\" class=\"drug drug_general\">ephedrine</a> 5 to 10 mg) as appropriate, with repeated doses if necessary. If hypotension persists, a continuous infusion of phenylephrine is administered (at 10 to 200 <span class=\"nowrap\">mcg/minute;</span> 0.1 to 2 <span class=\"nowrap\">mcg/kg/minute)</span>.</p><p/><p class=\"bulletIndent1\">Vasoplegia (ie, severe or refractory hypotension with low systemic vascular resistance [SVR]) due to factors such as prior administration of angiotensin-converting enzyme (ACE) inhibitors or septic shock is treated with the potent direct peripheral vasoconstrictor <a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">vasopressin</a> (at 1 to 4 <span class=\"nowrap\">units/hour;</span> 0.01 to 0.067 <span class=\"nowrap\">units/minute)</span> or <a href=\"topic.htm?path=norepinephrine-noradrenaline-drug-information\" class=\"drug drug_general\">norepinephrine</a> (at 1 to 30 <span class=\"nowrap\">mcg/minute;</span> 0.01 to 0.3 <span class=\"nowrap\">mcg/kg/minute)</span>. Vasopressin is also a good choice for treating systemic arterial hypotension in patients with pulmonary hypertension since it has a more selective systemic vasoconstricting effect than <a href=\"topic.htm?path=phenylephrine-drug-information\" class=\"drug drug_general\">phenylephrine</a> or norepinephrine, thereby sparing the pulmonary vasculature (<a href=\"image.htm?imageKey=ANEST%2F96387\" class=\"graphic graphic_table graphicRef96387 \">table 5</a>) [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/45\" class=\"abstract_t\">45</a>].</p><p/><p class=\"bulletIndent1\">Inotropic support may be needed for treatment of persistent hypotension caused by left or right ventricular dysfunction. Commonly employed agents include <a href=\"topic.htm?path=epinephrine-adrenaline-drug-information\" class=\"drug drug_general\">epinephrine</a> (at 1 to 100 <span class=\"nowrap\">mcg/minute;</span> 0.01 to 1 <span class=\"nowrap\">mcg/kg/minute),</span> <a href=\"topic.htm?path=norepinephrine-noradrenaline-drug-information\" class=\"drug drug_general\">norepinephrine</a> (at 1 to 30 <span class=\"nowrap\">mcg/minute;</span> 0.01 to 0.3 <span class=\"nowrap\">mcg/kg/minute),</span> or <a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">dopamine</a> (at 5 to 20 <span class=\"nowrap\">mcg/kg/minute)</span> (<a href=\"image.htm?imageKey=ANEST%2F96387\" class=\"graphic graphic_table graphicRef96387 \">table 5</a>). An intra-arterial catheter for continuous BP monitoring is necessary during titration of potent inotropic and vasopressor infusions.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Maintain oxygen carrying capacity of the blood </strong>&ndash; Administer supplemental oxygen to achieve a hemoglobin saturation &ge;95 percent. Also, to optimize oxygen delivery, we transfuse red blood cells if hemoglobin is &le;8 <span class=\"nowrap\">g/dL</span> in patients with stable ischemic heart disease [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/46\" class=\"abstract_t\">46</a>] (or &le;9 <span class=\"nowrap\">g/dL</span> in patients with recent myocardial infarction (MI) or unstable angina [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/47,48\" class=\"abstract_t\">47,48</a>]), particularly if there is evidence of ongoing bleeding, hypovolemia, or cardiac or other organ ischemia [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/49\" class=\"abstract_t\">49</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Prevent and treat hypothermia </strong>&ndash; Warm fluids prior to administration. Blankets and forced-air devices should be used for active warming and avoidance of hypothermia.</p><p/><p class=\"headingAnchor\" id=\"H712337663\"><span class=\"h1\">MANAGEMENT OF ANESTHESIA</span></p><p class=\"headingAnchor\" id=\"H18796184\"><span class=\"h2\">Premedication</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Regardless of the anesthetic technique that is selected, pain or anxiety causing tachycardia and hypertension in the preoperative period is treated (see <a href=\"#H213850611\" class=\"local\">'Prevention of ischemia'</a> above). If the patient is in a monitored setting, <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a> 1 to 4 mg is often used shortly before (within 30 to 60 minutes) or during induction of general anesthesia as an adjunct to alleviate anxiety. However, since midazolam may cause mild decreases in systemic blood pressure (BP) and cardiac output [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/50\" class=\"abstract_t\">50</a>], the dose is reduced or eliminated in hypovolemic patients and in the elderly (see <a href=\"topic.htm?path=anesthesia-for-the-older-adult#H183400987\" class=\"medical medical_review\">&quot;Anesthesia for the older adult&quot;, section on 'Anxiolytics'</a>). Similarly, small doses of an opioid (eg, <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> 25 to 50 mcg) may be administered to treat preoperative pain in a monitored setting, with care to avoid respiratory depression. (See <a href=\"topic.htm?path=anesthesia-for-the-older-adult#H183401005\" class=\"medical medical_review\">&quot;Anesthesia for the older adult&quot;, section on 'Opioids'</a>.)</p><p class=\"headingAnchor\" id=\"H18796197\"><span class=\"h2\">Selection of anesthetic technique</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The choice of anesthetic technique should be guided primarily by the requirements for the procedure, patient comorbidities, and preferences of the patient, surgeon, and anesthesiologist. </p><p>For major open abdominal or thoracic surgery, we suggest a neuraxial technique in addition to general anesthesia unless contraindicated or refused by the patient. Use of neuraxial anesthetic techniques may provide superior postoperative pain control when compared with systemic opioids. Also, stress-induced increases in heart rate may be attenuated via blockade of cardiac accelerator sympathetic fibers. In patients undergoing a major surgical procedure with high cardiac risk (open abdominal aortic surgery), a 2016 systematic review showed that addition of epidural analgesia to general anesthesia reduced risk of postoperative myocardial infarction (MI) as well as respiratory failure, and provided superior pain relief compared with systemic opioid-based analgesia, but there was no difference in mortality (1498 patients; 15 trials) [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/51\" class=\"abstract_t\">51</a>]. In patients undergoing any type of surgery (minor as well as major procedures), a 2014 overview of nine systematic reviews of randomized controlled clinical trials summarized outcomes with use of neuraxial analgesia (with or without general anesthesia) compared with general anesthesia alone [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/52\" class=\"abstract_t\">52</a>]. Use of neuraxial blockade alone reduced risk of postoperative pneumonia and 30-day mortality compared with general anesthesia alone, but there was no reduction in risk for MI. Choice of anesthetic technique to manage perioperative pain and other outcomes is discussed further in separate topics: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=management-of-acute-perioperative-pain#H447933291\" class=\"medical medical_review\">&quot;Management of acute perioperative pain&quot;, section on 'Strategy for perioperative pain control'</a>.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=anesthesia-for-open-abdominal-aortic-surgery#H1058594043\" class=\"medical medical_review\">&quot;Anesthesia for open abdominal aortic surgery&quot;, section on 'Postoperative pain management'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=anesthesia-for-open-pulmonary-resection#H642462442\" class=\"medical medical_review\">&quot;Anesthesia for open pulmonary resection&quot;, section on 'Postoperative pain management'</a>.)</p><p/><p>We do not place neuraxial needles or catheters in patients currently receiving anticoagulant drugs or antiplatelet therapy (other than <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> alone) because of increased risk for spinal epidural hematoma (SEH).&nbsp;Neuraxial needle or catheter placement may be employed in patients who will subsequently require intraoperative anticoagulation with intravenous heparin (eg, AAA surgery). There is extensive experience with the safe use of therapeutic intraoperative <a href=\"topic.htm?path=heparin-unfractionated-drug-information\" class=\"drug drug_general\">unfractionated heparin</a> in patients with epidural catheters when the heparin was given at least one hour after needle or catheter insertion into the neuraxial space [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/53\" class=\"abstract_t\">53</a>]. Subsequent removal of a neuraxial catheter, usually in the postoperative period, should occur only after restoration of normal coagulation status for several hours. (See <a href=\"topic.htm?path=neuraxial-anesthesia-analgesia-techniques-in-the-patient-receiving-anticoagulant-or-antiplatelet-medication\" class=\"medical medical_review\">&quot;Neuraxial anesthesia/analgesia techniques in the patient receiving anticoagulant or antiplatelet medication&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H132653745\"><span class=\"h2\">Local anesthesia with monitored anesthesia care</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with ischemic heart disease receiving monitored anesthesia care (MAC), key issues are avoidance of tachycardia and hypertension caused by pain <span class=\"nowrap\">and/or</span> anxiety, because these hemodynamic changes increase myocardial oxygen demand <span class=\"nowrap\">and/or</span> decrease myocardial oxygen supply (see <a href=\"#H213850611\" class=\"local\">'Prevention of ischemia'</a> above). Thus, small doses of short-acting agents (eg, <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a>, opioids, <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>) are administered to provide analgesia, anxiolysis, <span class=\"nowrap\">and/or</span> sedation. In patients with ischemic heart disease, it is particularly important to employ continuous monitoring to detect changes such as development of hypotension or respiratory depression with resultant hypoxemia.</p><p class=\"headingAnchor\" id=\"H114455658\"><span class=\"h2\">Neuraxial regional anesthesia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The goal of neuraxial anesthesia in appropriate candidates (eg, those who are not receiving antiplatelet and anticoagulant medications and who consent to the procedure) is to produce adequate anesthesia during the intraoperative period <span class=\"nowrap\">and/or</span> analgesia in the postoperative period without inducing hypotension that will compromise myocardial oxygen balance.</p><p>Neuraxial anesthesia can decrease cardiac preload due to sympathetic blockade, with resultant hypotension. This is more likely to occur in patients with intravascular volume depletion or in those with heart failure and diastolic dysfunction who are dependent upon adequate preload. In these patients, we employ a modified neuraxial anesthetic technique (eg, a low-dose combined spinal&ndash;epidural with or without intrathecal opioids, or a slowly titrated epidural anesthetic).</p><p>During onset of the block, fluid is administered to prevent hypotension. However, we avoid overhydration <span class=\"nowrap\">and/or</span> rapid administration of large fluid boluses in patients with symptomatic heart failure. Reduced volumes of crystalloid and slower administration are appropriate (eg, administration in 250-mL increments as needed, with monitoring of the patient&rsquo;s hemodynamic and clinical response to each increment).</p><p>A vasopressor is often necessary to restore BP to near-baseline levels. Significant hypotension is rapidly corrected by administering an alpha<sub>1</sub> receptor agonist (eg, <a href=\"topic.htm?path=phenylephrine-drug-information\" class=\"drug drug_general\">phenylephrine</a> 40 to 100 mcg) <span class=\"nowrap\">and/or</span> a <span class=\"nowrap\">direct/indirect</span> sympathomimetic with beta and alpha agonist effects (eg, <a href=\"topic.htm?path=ephedrine-systemic-drug-information\" class=\"drug drug_general\">ephedrine</a> 5 to 10 mg), with repeated doses as needed. (See <a href=\"#H319624669\" class=\"local\">'Treatment of ischemia'</a> above.)</p><p class=\"headingAnchor\" id=\"H160717850\"><span class=\"h2\">General anesthesia</span></p><p class=\"headingAnchor\" id=\"H2200606372\"><span class=\"h3\">Induction</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The goal of general anesthetic induction is to produce unconsciousness and provide analgesia, muscle relaxation, and attenuation of the hemodynamic responses to intubation and surgical stimulation, while at the same time avoiding hemodynamic changes that would lead to myocardial oxygen imbalance and ischemia (see <a href=\"#H213850611\" class=\"local\">'Prevention of ischemia'</a> above).</p><p>When tracheal intubation is planned, a reasonable approach is induction with a short-acting hypnotic (eg, low dose of <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> [approximately 1 <span class=\"nowrap\">mg/kg])</span> combined with a small dose of an opioid (eg, <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> 1 to 2 <span class=\"nowrap\">mcg/kg)</span> and <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a> 50 to 100 mg to blunt the sympathetic response to laryngoscopy and intubation. Also, a muscle relaxant is administered to facilitate laryngoscopy. When a non-depolarizing neuromuscular blocking agent is chosen, anesthetic depth is maintained or deepened with a potent inhaled anesthetic (eg, <a href=\"topic.htm?path=sevoflurane-drug-information\" class=\"drug drug_general\">sevoflurane</a> or <a href=\"topic.htm?path=isoflurane-drug-information\" class=\"drug drug_general\">isoflurane</a>) while waiting the few minutes for adequate muscle paralysis to perform tracheal intubation.</p><p>Because it has minimal hemodynamic side effects, <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a> is an alternative anesthetic induction agent for patients with known severe cardiomyopathy, cardiogenic shock, or hemodynamic instability [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/54\" class=\"abstract_t\">54</a>]. A possible concern with the use of etomidate is that it inhibits the biosynthesis of cortisol, an effect that lasts &lt;24 hours following a single dose [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/55-60\" class=\"abstract_t\">55-60</a>] (see <a href=\"topic.htm?path=causes-of-primary-adrenal-insufficiency-addisons-disease#H12\" class=\"medical medical_review\">&quot;Causes of primary adrenal insufficiency (Addison's disease)&quot;, section on 'Drugs'</a>). The clinical significance of this finding is uncertain [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/55,59,61\" class=\"abstract_t\">55,59,61</a>]. (See <a href=\"topic.htm?path=general-anesthesia-intravenous-induction-agents#H307136729\" class=\"medical medical_review\">&quot;General anesthesia: Intravenous induction agents&quot;, section on 'Etomidate'</a> and <a href=\"topic.htm?path=induction-agents-for-rapid-sequence-intubation-in-adults-outside-the-operating-room#H5\" class=\"medical medical_review\">&quot;Induction agents for rapid sequence intubation in adults outside the operating room&quot;, section on 'Etomidate'</a>.)</p><p><a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">Propofol</a> is the most commonly used intravenous induction agent. In contrast to <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a>, propofol and most other anesthetic induction agents decrease systemic blood pressure (BP) by some combination of attenuated sympathetic tone (ie, decreased systemic vascular resistance [SVR]), increased venous pooling (reducing venous return), <span class=\"nowrap\">and/or</span> direct depression of myocardial contractility. Thus, in order to minimize hypotension, the initial propofol induction dose is reduced to approximately 1 <span class=\"nowrap\">mg/kg</span> or less, and bolus injections may be administered in divided doses in older patients and others susceptible to developing hypotension (eg, patients with intravascular volume depletion and patients with diastolic dysfunction who are dependent upon adequate preload) [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/54,62\" class=\"abstract_t\">54,62</a>]. Small doses of an alpha<sub>1</sub> receptor agonist (eg, <a href=\"topic.htm?path=phenylephrine-drug-information\" class=\"drug drug_general\">phenylephrine</a> 40 to 100 mcg) can be given prophylactically or, if hypotension develops, following propofol induction. (See <a href=\"topic.htm?path=general-anesthesia-intravenous-induction-agents#H2269410\" class=\"medical medical_review\">&quot;General anesthesia: Intravenous induction agents&quot;, section on 'Propofol'</a> and <a href=\"topic.htm?path=anesthesia-for-the-older-adult#H183400993\" class=\"medical medical_review\">&quot;Anesthesia for the older adult&quot;, section on 'Sedative-hypnotics'</a>.)</p><p>We typically avoid <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> in patients with ischemic heart disease because administration usually results in significant increases in heart rate, mean arterial pressure, and plasma <a href=\"topic.htm?path=epinephrine-adrenaline-drug-information\" class=\"drug drug_general\">epinephrine</a> levels due to centrally mediated sympathetic nervous system stimulation. The increased heart rate, in particular, is undesirable. Some clinicians select a combination of induction agents in patients with ischemic heart disease and coexisting cardiomyopathy, with administration of ketamine 30 to 60 mg and a low dose of <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> 20 to 30 mg to produce unconsciousness while maintaining coronary perfusion, and <a href=\"topic.htm?path=esmolol-drug-information\" class=\"drug drug_general\">esmolol</a> 20 to 40 mg is coadministered to prevent tachycardia. (See <a href=\"#H213850611\" class=\"local\">'Prevention of ischemia'</a> above and <a href=\"topic.htm?path=general-anesthesia-intravenous-induction-agents#H2269465\" class=\"medical medical_review\">&quot;General anesthesia: Intravenous induction agents&quot;, section on 'Ketamine'</a>.)</p><p>When tracheal intubation is not needed for the surgical procedure, a laryngeal mask airway may be placed following intravenous induction of anesthesia with <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>. Again, dose adjustment may be required in patients with an ischemic cardiomyopathy.</p><p class=\"headingAnchor\" id=\"H2200606364\"><span class=\"h3\">Maintenance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For maintenance of anesthesia, either administration of a volatile inhalation agent or a total intravenous anesthetic (TIVA) technique is a reasonable choice, based on surgery-specific or patient-specific factors [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/1,2,44\" class=\"abstract_t\">1,2,44</a>]. In most patients, we prefer a volatile anesthetic (eg, <a href=\"topic.htm?path=sevoflurane-drug-information\" class=\"drug drug_general\">sevoflurane</a>, <a href=\"topic.htm?path=isoflurane-drug-information\" class=\"drug drug_general\">isoflurane</a>, or <a href=\"topic.htm?path=desflurane-drug-information\" class=\"drug drug_general\">desflurane</a>) as the primary agent to maintain general anesthesia. Doses of an opioid <span class=\"nowrap\">and/or</span> other intravenous (IV) adjuvant agents (eg, <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, neuromuscular blocking agent [NMBA]) are typically administered to supplement and reduce the total required dose of the inhalation agent, since a predominant effect of volatile anesthetics is dose-dependent vasodilation with resultant decreases in SVR and BP.</p><p>While volatile anesthetics may have cardioprotective effects in vitro [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/63-65\" class=\"abstract_t\">63-65</a>], these have not convincingly been shown to be clinically significant in patients having noncardiac surgery. In a 2016 systematic review of 45 randomized trials of the effects of volatile anesthetics versus TIVA on mortality and postoperative morbidity in patients undergoing general anesthesia, volatile anesthetic agents significantly reduced overall cardiac events and postoperative morbidity in patients undergoing cardiac surgery, but not in patients undergoing noncardiac surgery [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/66\" class=\"abstract_t\">66</a>]. These findings are not conclusive as the analysis did not distinguish between patients having different types of cardiac surgery (eg, coronary versus valve) or noncardiac surgery (vascular versus nonvascular), and that factor may impact the magnitude of benefit. However, individual trials in specific patient populations have reported similar results. For example, one trial included in the meta-analysis assigned 385 noncardiac surgical patients with high cardiovascular risk to receive either <a href=\"topic.htm?path=sevoflurane-drug-information\" class=\"drug drug_general\">sevoflurane</a> or TIVA; no differences were noted in the primary composite endpoint of myocardial ischemia detected by continuous electrocardiography (ECG) or troponin elevation [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/67\" class=\"abstract_t\">67</a>]. Similarly, studies conducted in patients undergoing major vascular surgery have not observed a benefit of sevoflurane over TIVA. (See <a href=\"topic.htm?path=anesthesia-for-open-abdominal-aortic-surgery#H2994974110\" class=\"medical medical_review\">&quot;Anesthesia for open abdominal aortic surgery&quot;, section on 'General anesthesia'</a>.)</p><p class=\"headingAnchor\" id=\"H2200607745\"><span class=\"h3\">Emergence</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>During emergence, sympathetic stimulation caused by excitement and pain, as well as stimulation of airway reflexes during tracheal extubation, increase the potential for tachycardia and hypertension. This may lead to myocardial ischemia. These hemodynamic changes are controlled by optimizing analgesia prior to emergence (eg, by administering a systemic opioid or doses of local anesthetic via an existing epidural catheter) <span class=\"nowrap\">and/or</span> by administering bolus doses of intravenous beta blockers (eg, <a href=\"topic.htm?path=esmolol-drug-information\" class=\"drug drug_general\">esmolol</a>, <a href=\"topic.htm?path=labetalol-drug-information\" class=\"drug drug_general\">labetalol</a>, or <a href=\"topic.htm?path=metoprolol-drug-information\" class=\"drug drug_general\">metoprolol</a>) <span class=\"nowrap\">and/or</span> vasodilating agents (eg, labetalol, <a href=\"topic.htm?path=nicardipine-drug-information\" class=\"drug drug_general\">nicardipine</a>, or <a href=\"topic.htm?path=nitroglycerin-glyceryl-trinitrate-drug-information\" class=\"drug drug_general\">nitroglycerin</a>) during and immediately after emergence and extubation.</p><p class=\"headingAnchor\" id=\"H31432339\"><span class=\"h2\">Management of arrhythmias</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Arrhythmias are not uncommon in patients with ischemic heart disease. Management of specific cardiac arrhythmias is the same as in other settings and is discussed in detail separately (see <a href=\"topic.htm?path=advanced-cardiac-life-support-acls-in-adults#H7\" class=\"medical medical_review\">&quot;Advanced cardiac life support (ACLS) in adults&quot;, section on 'Management of specific arrhythmias'</a>). Intraoperative management of serious arrhythmias is summarized below:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Ventricular fibrillation </strong>&ndash; Ventricular fibrillation or ventricular tachycardia is life-threatening and requires immediate defibrillation or cardioversion. If the arrhythmia recurs, antiarrhythmic therapy, particularly <a href=\"topic.htm?path=amiodarone-drug-information\" class=\"drug drug_general\">amiodarone</a>, may be effective. (See <a href=\"topic.htm?path=advanced-cardiac-life-support-acls-in-adults#H8\" class=\"medical medical_review\">&quot;Advanced cardiac life support (ACLS) in adults&quot;, section on 'Ventricular fibrillation and pulseless ventricular tachycardia'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Atrial fibrillation </strong>&ndash; Atrial fibrillation is a common arrhythmia, particularly in patients with underlying heart disease. In patients who are hemodynamically unstable (eg, myocardial ischemia, hypotension, pulmonary edema) due to atrial fibrillation with a rapid ventricular response, treatment options include intravenous rate control medications <span class=\"nowrap\">and/or</span> cardioversion. Administration of rapidly acting drugs such as <a href=\"topic.htm?path=esmolol-drug-information\" class=\"drug drug_general\">esmolol</a>, <a href=\"topic.htm?path=diltiazem-drug-information\" class=\"drug drug_general\">diltiazem</a>, or <a href=\"topic.htm?path=amiodarone-drug-information\" class=\"drug drug_general\">amiodarone</a> may control ventricular rate. However, if the atrial fibrillation is associated with hypotension or evidence of cardiogenic shock, or it is clearly the cause of pulmonary edema, immediate cardioversion to restore sinus rhythm may be necessary. (See <a href=\"topic.htm?path=atrial-fibrillation-cardioversion-to-sinus-rhythm\" class=\"medical medical_review\">&quot;Atrial fibrillation: Cardioversion to sinus rhythm&quot;</a> and <a href=\"topic.htm?path=control-of-ventricular-rate-in-atrial-fibrillation-pharmacologic-therapy#H6\" class=\"medical medical_review\">&quot;Control of ventricular rate in atrial fibrillation: Pharmacologic therapy&quot;, section on 'Urgency of therapy'</a> and <a href=\"topic.htm?path=control-of-ventricular-rate-in-atrial-fibrillation-pharmacologic-therapy#H9\" class=\"medical medical_review\">&quot;Control of ventricular rate in atrial fibrillation: Pharmacologic therapy&quot;, section on 'Pharmacologic treatment'</a>.)</p><p/><p class=\"bulletIndent1\">Decisions regarding long-term anticoagulation are made in consultation with the cardiologist in the early postoperative period, after the patient has been stabilized. (See <a href=\"topic.htm?path=prevention-of-embolization-prior-to-and-after-restoration-of-sinus-rhythm-in-atrial-fibrillation\" class=\"medical medical_review\">&quot;Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Bradycardia </strong>&ndash; Severe bradycardia (eg, heart rate &lt;40 <span class=\"nowrap\">beats/minute</span> [bpm]) may result in signs and symptoms of inadequate perfusion (eg, hypotension, altered mental status) and is usually treated with <a href=\"topic.htm?path=glycopyrrolate-glycopyrronium-drug-information\" class=\"drug drug_general\">glycopyrrolate</a>, <a href=\"topic.htm?path=atropine-drug-information\" class=\"drug drug_general\">atropine</a>, or <a href=\"topic.htm?path=ephedrine-systemic-drug-information\" class=\"drug drug_general\">ephedrine</a>, while preparations are made for transcutaneous pacing <span class=\"nowrap\">and/or</span> a potent chronotropic agent (eg, <a href=\"topic.htm?path=epinephrine-adrenaline-drug-information\" class=\"drug drug_general\">epinephrine</a>) (see <a href=\"topic.htm?path=advanced-cardiac-life-support-acls-in-adults#H11\" class=\"medical medical_review\">&quot;Advanced cardiac life support (ACLS) in adults&quot;, section on 'Bradycardia'</a>). Administration of atropine, ephedrine, or epinephrine may cause tachycardia, which is undesirable in the setting of myocardial ischemia, but may be further managed following treatment of severe bradycardia.</p><p/><p class=\"headingAnchor\" id=\"H117881860\"><span class=\"h2\">Control of glucose</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We maintain perioperative glucose &lt;180 <span class=\"nowrap\">mg/dL</span> (&lt;10 <span class=\"nowrap\">mmol/L)</span> in patients with ischemic heart disease and take care to avoid hypoglycemic episodes. Although hyperglycemia is associated with an approximately two- to fourfold increased risk of a myocardial ischemic event in vascular and other noncardiac surgery [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/68,69\" class=\"abstract_t\">68,69</a>], hypoglycemia is also detrimental. A trial in critically ill patients showed that attempts to tightly control serum glucose (81 to 108 <span class=\"nowrap\">mg/dL</span> [4.5 to 6.0 <span class=\"nowrap\">mmol/L])</span> are associated with more hypoglycemic episodes and higher mortality compared with more liberal glucose management (&lt;180 <span class=\"nowrap\">mg/dL</span> [&lt;10 <span class=\"nowrap\">mmol/L])</span> [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/70\" class=\"abstract_t\">70</a>]. (See <a href=\"topic.htm?path=glycemic-control-and-intensive-insulin-therapy-in-critical-illness\" class=\"medical medical_review\">&quot;Glycemic control and intensive insulin therapy in critical illness&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H213852252\"><span class=\"h1\">POSTOPERATIVE MANAGEMENT</span></p><p class=\"headingAnchor\" id=\"H213852241\"><span class=\"h2\">Monitoring for myocardial injury</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most myocardial injury after noncardiac surgery (MINS) occurs in the postoperative period [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/1\" class=\"abstract_t\">1</a>]. For patients with ischemic heart disease at high cardiac risk (<a href=\"image.htm?imageKey=CARD%2F57075\" class=\"graphic graphic_table graphicRef57075 \">table 1</a>), reasonable precautions include continuous electrocardiography (ECG) monitoring in the post-anesthesia care unit and subsequently in an intensive care unit or stepdown unit so that tachycardia can be avoided or treated [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/71\" class=\"abstract_t\">71</a>], and evidence of ischemia may be detected. (See <a href=\"topic.htm?path=perioperative-myocardial-infarction-or-injury-after-noncardiac-surgery\" class=\"medical medical_review\">&quot;Perioperative myocardial infarction or injury after noncardiac surgery&quot;</a>.)</p><p>In addition, all patients with symptoms or ECG changes suggestive of ischemia or myocardial infarction (MI), as well as asymptomatic patients with high cardiac risk (<a href=\"image.htm?imageKey=CARD%2F57075\" class=\"graphic graphic_table graphicRef57075 \">table 1</a>), should be monitored for MINS with troponin measurements and 12-lead ECGs. This is discussed in detail separately. (See <a href=\"topic.htm?path=perioperative-myocardial-infarction-or-injury-after-noncardiac-surgery#H530579546\" class=\"medical medical_review\">&quot;Perioperative myocardial infarction or injury after noncardiac surgery&quot;, section on 'Screening'</a>.)</p><p class=\"headingAnchor\" id=\"H213852141\"><span class=\"h2\">Management of pain</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Effective postoperative pain management is important to avoid stress, adverse hemodynamics, and hypercoagulable states [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/1\" class=\"abstract_t\">1</a>]. For cooperative patients without contraindications undergoing major abdominal or thoracic surgery with a large incision, we suggest epidural anesthesia for preemptive postoperative analgesia. Alternatively, subarachnoid administration of a longer-acting opiate (eg, <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> or <a href=\"topic.htm?path=hydromorphone-drug-information\" class=\"drug drug_general\">hydromorphone</a>) may be administered to provide 12 to 24 hours of postoperative analgesia. (See <a href=\"topic.htm?path=management-of-acute-perioperative-pain#H795594911\" class=\"medical medical_review\">&quot;Management of acute perioperative pain&quot;, section on 'Regional analgesia'</a> and <a href=\"#H114455658\" class=\"local\">'Neuraxial regional anesthesia'</a> above.)</p><p>Specific regional anesthetic techniques may also be effective, and these are chosen based on the surgical site and procedure (eg, brachial plexus blocks for upper extremity pain; femoral or sciatic nerve blocks for lower extremity pain; intercostal or paravertebral nerve blocks for breast, thoracic, or upper abdominal procedures). (See <a href=\"topic.htm?path=management-of-acute-perioperative-pain#H795596357\" class=\"medical medical_review\">&quot;Management of acute perioperative pain&quot;, section on 'Peripheral nerve blocks'</a>.)</p><p>Other techniques for management of postoperative pain, including patient-controlled analgesia (PCA), are discussed in detail elsewhere. (See <a href=\"topic.htm?path=management-of-acute-perioperative-pain\" class=\"medical medical_review\">&quot;Management of acute perioperative pain&quot;</a>.)</p><p>Nonselective nonsteroidal antiinflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) inhibitors are avoided in patients with myocardial ischemia; these agents carry a boxed warning regarding cardiovascular risk [<a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/2\" class=\"abstract_t\">2</a>]. (See <a href=\"topic.htm?path=nonselective-nsaids-adverse-cardiovascular-effects\" class=\"medical medical_review\">&quot;Nonselective NSAIDs: Adverse cardiovascular effects&quot;</a> and <a href=\"topic.htm?path=cox-2-selective-inhibitors-adverse-cardiovascular-effects\" class=\"medical medical_review\">&quot;COX-2 selective inhibitors: Adverse cardiovascular effects&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H1877424708\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-perioperative-cardiovascular-evaluation-and-management\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Perioperative cardiovascular evaluation and management&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H114455937\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with ischemic heart disease have increased risk for perioperative myocardial injury after noncardiac surgery (MINS), particularly after recent myocardial infarction (MI) or percutaneous coronary intervention (PCI), and during urgent or emergency surgery or certain high-risk surgical procedures (<a href=\"image.htm?imageKey=CARD%2F57075\" class=\"graphic graphic_table graphicRef57075 \">table 1</a> and <a href=\"image.htm?imageKey=CARD%2F96563\" class=\"graphic graphic_algorithm graphicRef96563 \">algorithm 1</a>). (See <a href=\"#H132216315\" class=\"local\">'Evaluation and management of high cardiac risk'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Screening for MINS is performed in patients with high cardiac risk (<a href=\"image.htm?imageKey=CARD%2F57075\" class=\"graphic graphic_table graphicRef57075 \">table 1</a>), particularly if a high-risk surgical procedure is planned (<a href=\"image.htm?imageKey=CARD%2F57828\" class=\"graphic graphic_table graphicRef57828 \">table 2</a> and <a href=\"image.htm?imageKey=ANEST%2F116645\" class=\"graphic graphic_table graphicRef116645 \">table 3</a>). This includes preoperative baseline cardiac troponin level and resting 12-lead electrocardiogram (ECG). (See <a href=\"topic.htm?path=evaluation-of-cardiac-risk-prior-to-noncardiac-surgery\" class=\"medical medical_review\">&quot;Evaluation of cardiac risk prior to noncardiac surgery&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chronically administered beta blockers, statins, <a href=\"topic.htm?path=clonidine-drug-information\" class=\"drug drug_general\">clonidine</a>, calcium channel blockers, and <a href=\"topic.htm?path=digoxin-drug-information\" class=\"drug drug_general\">digoxin</a> are continued in the perioperative period. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are typically continued, but may be held on the morning of surgery if large perioperative fluid shifts are anticipated. Administration of <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> in the preoperative period depends upon specific patient and surgical factors. (See <a href=\"#H18794857\" class=\"local\">'Preoperative medication management'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Optimizing myocardial oxygen (O<sub>2</sub>) supply and minimizing demand are the primary anesthetic goals. The following general approach is suggested (see <a href=\"#H213850611\" class=\"local\">'Prevention of ischemia'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Low to normal heart rate (eg, 50 to 80 <span class=\"nowrap\">beats/minute</span> [bpm])</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Normal to high blood pressure (BP) within 20 percent of baseline (typically a mean arterial BP 75 to 95 mmHg <span class=\"nowrap\">and/or</span> diastolic BP 65 to 95 mmHg)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Normal left ventricular end-diastolic volume (LVEDV) and avoidance of fluid overload</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Normal to high hemoglobin saturation, normothermia, and treatment of severe anemia (ie, hemoglobin level &lt;8 <span class=\"nowrap\">g/dL)</span></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Monitoring includes (see <a href=\"#H295569606\" class=\"local\">'Monitoring for ischemia'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Continuous ECG monitoring, ideally with computerized ST-segment analysis in all patients.</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Intra-arterial catheterization when moment-to-moment BP changes are anticipated <span class=\"nowrap\">and/or</span> to guide management of vasoactive drugs.</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Central venous catheterization when significant blood loss, large fluid shifts, or the need to administer vasoactive drugs is likely.</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Perioperative transesophageal echocardiography (TEE) to determine the cause of unexplained persistent or life-threatening circulatory instability (&ldquo;rescue echo&rdquo;).</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>We recommend against pulmonary artery catheter (PAC) catheterization for monitoring for ischemia (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Suspected ischemia is managed as follows (see <a href=\"#H319624669\" class=\"local\">'Treatment of ischemia'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Treat tachycardia <span class=\"nowrap\">and/or</span> hypertension caused by pain or light anesthesia by administering an opioid, deepening general anesthesia, or re-administering local anesthesia via an epidural. An intravenous (IV) beta blocker (eg, <a href=\"topic.htm?path=esmolol-drug-information\" class=\"drug drug_general\">esmolol</a>, <a href=\"topic.htm?path=metoprolol-drug-information\" class=\"drug drug_general\">metoprolol</a>, or <a href=\"topic.htm?path=labetalol-drug-information\" class=\"drug drug_general\">labetalol</a>) may be necessary to restore heart rate (HR) <span class=\"nowrap\">and/or</span> BP to baseline levels, or a vasodilating agent (eg, <a href=\"topic.htm?path=nicardipine-drug-information\" class=\"drug drug_general\">nicardipine</a> or <a href=\"topic.htm?path=nitroglycerin-glyceryl-trinitrate-drug-information\" class=\"drug drug_general\">nitroglycerin</a>) may be necessary to control BP.</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Persistent myocardial ischemia associated with hypertension is treated with an IV <a href=\"topic.htm?path=nitroglycerin-glyceryl-trinitrate-drug-information\" class=\"drug drug_general\">nitroglycerin</a> infusion (at 10 to 400 <span class=\"nowrap\">mcg/minute;</span> 0.1 to 4 <span class=\"nowrap\">mcg/kg/minute)</span>.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Treat hypotension (ie, mean BP &lt;75 mmHg or diastolic BP &lt;65 mmHg) by reducing excessive anesthetic depth and administering intravenous fluid and boluses of a vasopressor (eg, <a href=\"topic.htm?path=phenylephrine-drug-information\" class=\"drug drug_general\">phenylephrine</a> 40 to 100 mcg <span class=\"nowrap\">and/or</span> <a href=\"topic.htm?path=ephedrine-systemic-drug-information\" class=\"drug drug_general\">ephedrine</a> 5 to 10 mg).</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Persistent hypotension is treated with a titrated continuous infusion of <a href=\"topic.htm?path=phenylephrine-drug-information\" class=\"drug drug_general\">phenylephrine</a> (at 10 to 200 <span class=\"nowrap\">mcg/minute;</span> 0.1 to 2.0 <span class=\"nowrap\">mcg/kg/minute)</span> or an inotropic agent if left or right ventricular dysfunction is suspected.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Correct hypoxemia (ie, hemoglobin saturation &lt;95 percent) and severe anemia (ie, hemoglobin level &lt;8 <span class=\"nowrap\">g/dL)</span>.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Prevent and treat hypothermia by warming fluids prior to administration and using blankets and forced-air devices.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The choice of anesthetic technique should be guided primarily by the requirements for the procedure, patient comorbidities, and preferences of the patient, surgeon, and anesthesiologist. For perioperative pain control in patients undergoing major open abdominal or thoracic surgery, we suggest a neuraxial technique in addition to general anesthesia when appropriate (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H114455658\" class=\"local\">'Neuraxial regional anesthesia'</a> above and <a href=\"#H213852141\" class=\"local\">'Management of pain'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>During onset of a neuraxial block, crystalloid is administered in 250-mL increments to prevent hypotension. Significant hypotension is immediately corrected by administration of boluses of a vasopressor agent (eg, <a href=\"topic.htm?path=phenylephrine-drug-information\" class=\"drug drug_general\">phenylephrine</a> 40 to 100 mcg <span class=\"nowrap\">and/or</span> <a href=\"topic.htm?path=ephedrine-systemic-drug-information\" class=\"drug drug_general\">ephedrine</a> 5 to 10 mg). (See <a href=\"#H114455658\" class=\"local\">'Neuraxial regional anesthesia'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The goal of general anesthetic induction is to attenuate hemodynamic responses to tracheal intubation (eg, tachycardia and hypertension) without causing hemodynamic changes that would lead to myocardial ischemia. A reasonable approach is induction with a short-acting hypnotic (eg, <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a> 0.3 <span class=\"nowrap\">mg/kg</span> or a low dose of <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> [approximately 1 <span class=\"nowrap\">mg/kg]</span> administered slowly) combined with a moderate dose of an opioid (eg, <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> 1 to 2 <span class=\"nowrap\">mcg/kg)</span> <span class=\"nowrap\">and/or</span> <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a> 50 to 100 mg to blunt the sympathetic response to laryngoscopy and intubation. Also, a muscle relaxant is administered to facilitate laryngoscopy. (See <a href=\"#H2200606372\" class=\"local\">'Induction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For maintenance of anesthesia, use of a volatile inhalational agent (eg, <a href=\"topic.htm?path=sevoflurane-drug-information\" class=\"drug drug_general\">sevoflurane</a>, <a href=\"topic.htm?path=isoflurane-drug-information\" class=\"drug drug_general\">isoflurane</a>, or <a href=\"topic.htm?path=desflurane-drug-information\" class=\"drug drug_general\">desflurane</a>) as the primary technique or administration of total IV anesthesia (TIVA) are both reasonable choices. (See <a href=\"#H2200606364\" class=\"local\">'Maintenance'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prevent or control tachycardia and hypertension during emergence from anesthesia by optimizing analgesia prior to emergence (eg, with IV opioid or doses of local anesthetic via an existing epidural catheter), and administer IV beta blockers (eg, <a href=\"topic.htm?path=esmolol-drug-information\" class=\"drug drug_general\">esmolol</a>, <a href=\"topic.htm?path=labetalol-drug-information\" class=\"drug drug_general\">labetalol</a>, or <a href=\"topic.htm?path=metoprolol-drug-information\" class=\"drug drug_general\">metoprolol</a>) or vasodilating agents (eg, <a href=\"topic.htm?path=nicardipine-drug-information\" class=\"drug drug_general\">nicardipine</a> or <a href=\"topic.htm?path=nitroglycerin-glyceryl-trinitrate-drug-information\" class=\"drug drug_general\">nitroglycerin</a>) if necessary. (See <a href=\"#H2200607745\" class=\"local\">'Emergence'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Postoperative screening for MINS is employed in all patients with symptoms or ECG changes suggestive of ischemia or MI, as well as asymptomatic patients with high cardiac risk (<a href=\"image.htm?imageKey=CARD%2F57075\" class=\"graphic graphic_table graphicRef57075 \">table 1</a>). This includes continuous ECG monitoring in the post-anesthesia care unit and subsequently in an intensive care unit or stepdown unit, as well as serial troponin measurements and 12-lead ECGs. (See <a href=\"topic.htm?path=perioperative-myocardial-infarction-or-injury-after-noncardiac-surgery#H530579546\" class=\"medical medical_review\">&quot;Perioperative myocardial infarction or injury after noncardiac surgery&quot;, section on 'Screening'</a>.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/1\" class=\"nounderline abstract_t\">Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130:2215.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/2\" class=\"nounderline abstract_t\">Kristensen SD, Knuuti J. New ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. Eur Heart J 2014; 35:2344.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/3\" class=\"nounderline abstract_t\">Rodriguez A, Guilera N, Mases A, et al. Management of antiplatelet therapy in patients with coronary stents undergoing noncardiac surgery: association with adverse events. Br J Anaesth 2018; 120:67.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/4\" class=\"nounderline abstract_t\">Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J 2014; 35:2383.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/5\" class=\"nounderline abstract_t\">Liu JB, Liu Y, Cohen ME, et al. Defining the Intrinsic Cardiac Risks of Operations to Improve Preoperative Cardiac Risk Assessments. Anesthesiology 2018; 128:283.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/6\" class=\"nounderline abstract_t\">Devereaux PJ, Mrkobrada M, Sessler DI, et al. Aspirin in patients undergoing noncardiac surgery. N Engl J Med 2014; 370:1494.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/7\" class=\"nounderline abstract_t\">Zou Z, Yuan HB, Yang B, et al. Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults. Cochrane Database Syst Rev 2016; :CD009210.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/8\" class=\"nounderline abstract_t\">London MJ. Preoperative Administration of Angiotensin-converting Enzyme Inhibitors or Angiotensin II Receptor Blockers: Do We Have Enough &quot;VISION&quot; to Stop It? Anesthesiology 2017; 126:1.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/9\" class=\"nounderline abstract_t\">Roshanov PS, Rochwerg B, Patel A, et al. Withholding versus Continuing Angiotensin-converting Enzyme Inhibitors or Angiotensin II Receptor Blockers before Noncardiac Surgery: An Analysis of the Vascular events In noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort. Anesthesiology 2017; 126:16.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/10\" class=\"nounderline abstract_t\">WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128:e240.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/11\" class=\"nounderline abstract_t\">American Society of Anesthesiologists. Practice advisory for the perioperative management of patients with cardiac implantable electronic devices: pacemakers and implantable cardioverter-defibrillators: an updated report by the american society of anesthesiologists task force on perioperative management of patients with cardiac implantable electronic devices. Anesthesiology 2011; 114:247.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/12\" class=\"nounderline abstract_t\">Crossley GH, Poole JE, Rozner MA, et al. The Heart Rhythm Society (HRS)/American Society of Anesthesiologists (ASA) Expert Consensus Statement on the perioperative management of patients with implantable defibrillators, pacemakers and arrhythmia monitors: facilities and patient management this document was developed as a joint project with the American Society of Anesthesiologists (ASA), and in collaboration with the American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Heart Rhythm 2011; 8:1114.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/13\" class=\"nounderline abstract_t\">Andrews TC, Fenton T, Toyosaki N, et al. Subsets of ambulatory myocardial ischemia based on heart rate activity. Circadian distribution and response to anti-ischemic medication. The Angina and Silent Ischemia Study Group (ASIS). Circulation 1993; 88:92.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/14\" class=\"nounderline abstract_t\">Boerth RC, Covell JW, Pool PE, Ross J Jr. Increased myocardial oxygen consumption and contractile state associated with increased heart rate in dogs. Circ Res 1969; 24:725.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/15\" class=\"nounderline abstract_t\">Boudoulas H, Rittgers SE, Lewis RP, et al. Changes in diastolic time with various pharmacologic agents: implication for myocardial perfusion. Circulation 1979; 60:164.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/16\" class=\"nounderline abstract_t\">Chung CS, Karamanoglu M, Kov&aacute;cs SJ. Duration of diastole and its phases as a function of heart rate during supine bicycle exercise. Am J Physiol Heart Circ Physiol 2004; 287:H2003.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/17\" class=\"nounderline abstract_t\">Marik PE, Baram M, Vahid B. Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares. Chest 2008; 134:172.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/18\" class=\"nounderline abstract_t\">Mark JB. Central venous pressure monitoring: clinical insights beyond the numbers. J Cardiothorac Vasc Anesth 1991; 5:163.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/19\" class=\"nounderline abstract_t\">Barone JE, Tucker JB, Rassias D, Corvo PR. Routine perioperative pulmonary artery catheterization has no effect on rate of complications in vascular surgery: a meta-analysis. Am Surg 2001; 67:674.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/20\" class=\"nounderline abstract_t\">Mark JB. Multimodal detection of perioperative myocardial ischemia. Tex Heart Inst J 2005; 32:461.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/21\" class=\"nounderline abstract_t\">Ellis JE, Shah MN, Briller JE, et al. A comparison of methods for the detection of myocardial ischemia during noncardiac surgery: automated ST-segment analysis systems, electrocardiography, and transesophageal echocardiography. Anesth Analg 1992; 75:764.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/22\" class=\"nounderline abstract_t\">Leung JM, Voskanian A, Bellows WH, Pastor D. Automated electrocardiograph ST segment trending monitors: accuracy in detecting myocardial ischemia. Anesth Analg 1998; 87:4.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/23\" class=\"nounderline abstract_t\">Slogoff S, Keats AS, David Y, Igo SR. Incidence of perioperative myocardial ischemia detected by different electrocardiographic systems. Anesthesiology 1990; 73:1074.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/24\" class=\"nounderline abstract_t\">Maile MD, Engoren MC, Tremper KK, et al. Variability of Automated Intraoperative ST Segment Values Predicts Postoperative Troponin Elevation. Anesth Analg 2016; 122:608.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/25\" class=\"nounderline abstract_t\">London MJ, Hollenberg M, Wong MG, et al. Intraoperative myocardial ischemia: localization by continuous 12-lead electrocardiography. Anesthesiology 1988; 69:232.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/26\" class=\"nounderline abstract_t\">Landesberg G, Mosseri M, Wolf Y, et al. Perioperative myocardial ischemia and infarction: identification by continuous 12-lead electrocardiogram with online ST-segment monitoring. Anesthesiology 2002; 96:264.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/27\" class=\"nounderline abstract_t\">Cockings JG, Webb RK, Klepper ID, et al. The Australian Incident Monitoring Study. Blood pressure monitoring--applications and limitations: an analysis of 2000 incident reports. Anaesth Intensive Care 1993; 21:565.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/28\" class=\"nounderline abstract_t\">Marik PE, Cavallazzi R. Does the central venous pressure predict fluid responsiveness? An updated meta-analysis and a plea for some common sense. Crit Care Med 2013; 41:1774.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/29\" class=\"nounderline abstract_t\">Bentzer P, Griesdale DE, Boyd J, et al. Will This Hemodynamically Unstable Patient Respond to a Bolus of Intravenous Fluids? JAMA 2016; 316:1298.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/30\" class=\"nounderline abstract_t\">van Daele ME, Sutherland GR, Mitchell MM, et al. Do changes in pulmonary capillary wedge pressure adequately reflect myocardial ischemia during anesthesia? A correlative preoperative hemodynamic, electrocardiographic, and transesophageal echocardiographic study. Circulation 1990; 81:865.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/31\" class=\"nounderline abstract_t\">Sandham JD, Hull RD, Brant RF, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003; 348:5.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/32\" class=\"nounderline abstract_t\">Polanczyk CA, Rohde LE, Goldman L, et al. Right heart catheterization and cardiac complications in patients undergoing noncardiac surgery: an observational study. JAMA 2001; 286:309.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/33\" class=\"nounderline abstract_t\">Rajaram SS, Desai NK, Kalra A, et al. Pulmonary artery catheters for adult patients in intensive care. Cochrane Database Syst Rev 2013; :CD003408.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/34\" class=\"nounderline abstract_t\">Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery, European Society of Cardiology (ESC), Poldermans D, et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J 2009; 30:2769.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/35\" class=\"nounderline abstract_t\">Smith JS, Cahalan MK, Benefiel DJ, et al. Intraoperative detection of myocardial ischemia in high-risk patients: electrocardiography versus two-dimensional transesophageal echocardiography. Circulation 1985; 72:1015.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/36\" class=\"nounderline abstract_t\">Clements FM, de Bruijn NP. Perioperative evaluation of regional wall motion by transesophageal two-dimensional echocardiography. Anesth Analg 1987; 66:249.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/37\" class=\"nounderline abstract_t\">Kato M, Nakashima Y, Levine J, et al. Does transesophageal echocardiography improve postoperative outcome in patients undergoing coronary artery bypass surgery? J Cardiothorac Vasc Anesth 1993; 7:285.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/38\" class=\"nounderline abstract_t\">Gewertz BL, Kremser PC, Zarins CK, et al. Transesophageal echocardiographic monitoring of myocardial ischemia during vascular surgery. J Vasc Surg 1987; 5:607.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/39\" class=\"nounderline abstract_t\">Eisenberg MJ, London MJ, Leung JM, et al. Monitoring for myocardial ischemia during noncardiac surgery. A technology assessment of transesophageal echocardiography and 12-lead electrocardiography. The Study of Perioperative Ischemia Research Group. JAMA 1992; 268:210.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/40\" class=\"nounderline abstract_t\">London MJ, Tubau JF, Wong MG, et al. The &quot;natural history&quot; of segmental wall motion abnormalities in patients undergoing noncardiac surgery. S.P.I. Research Group. Anesthesiology 1990; 73:644.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/41\" class=\"nounderline abstract_t\">American Society of Anesthesiologists and Society of Cardiovascular Anesthesiologists Task Force on Transesophageal Echocardiography. Practice guidelines for perioperative transesophageal echocardiography. An updated report by the American Society of Anesthesiologists and the Society of Cardiovascular Anesthesiologists Task Force on Transesophageal Echocardiography. Anesthesiology 2010; 112:1084.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/42\" class=\"nounderline abstract_t\">Borer JS, Redwood DR, Levitt B, et al. Reduction in myocardial ischemia with nitroglycerin or nitroglycerin plus phenylephrine administered during acute myocardial infarction. N Engl J Med 1975; 293:1008.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/43\" class=\"nounderline abstract_t\">Hood WB Jr. Editorial: &quot;Dynamite pills&quot; in the coronary care unit? N Engl J Med 1975; 293:1040.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/44\" class=\"nounderline abstract_t\">Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2014; 64:e77.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/45\" class=\"nounderline abstract_t\">Augoustides JG, Savino JS. Vasopressin: the perioperative gift that keeps on giving. Anesthesiology 2014; 121:914.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/46\" class=\"nounderline abstract_t\">Carson JL, Grossman BJ, Kleinman S, et al. Red blood cell transfusion: a clinical practice guideline from the AABB*. Ann Intern Med 2012; 157:49.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/47\" class=\"nounderline abstract_t\">Murphy GJ, Pike K, Rogers CA, et al. Liberal or restrictive transfusion after cardiac surgery. N Engl J Med 2015; 372:997.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/48\" class=\"nounderline abstract_t\">Carson JL, Brooks MM, Abbott JD, et al. Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J 2013; 165:964.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/49\" class=\"nounderline abstract_t\">American Society of Anesthesiologists Task Force on Perioperative Blood Management. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management*. Anesthesiology 2015; 122:241.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/50\" class=\"nounderline abstract_t\">Reves JG, Fragen RJ, Vinik HR, Greenblatt DJ. Midazolam: pharmacology and uses. Anesthesiology 1985; 62:310.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/51\" class=\"nounderline abstract_t\">Guay J, Kopp S. Epidural pain relief versus systemic opioid-based pain relief for abdominal aortic surgery. Cochrane Database Syst Rev 2016; :CD005059.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/52\" class=\"nounderline abstract_t\">Guay J, Choi P, Suresh S, et al. Neuraxial blockade for the prevention of postoperative mortality and major morbidity: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev 2014; :CD010108.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/53\" class=\"nounderline abstract_t\">Liu SS, Mulroy MF. Neuraxial anesthesia and analgesia in the presence of standard heparin. Reg Anesth Pain Med 1998; 23:157.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/54\" class=\"nounderline abstract_t\">Das S, Forrest K, Howell S. General anaesthesia in elderly patients with cardiovascular disorders: choice of anaesthetic agent. Drugs Aging 2010; 27:265.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/55\" class=\"nounderline abstract_t\">Chan CM, Mitchell AL, Shorr AF. Etomidate is associated with mortality and adrenal insufficiency in sepsis: a meta-analysis*. Crit Care Med 2012; 40:2945.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/56\" class=\"nounderline abstract_t\">Lundy JB, Slane ML, Frizzi JD. Acute adrenal insufficiency after a single dose of etomidate. J Intensive Care Med 2007; 22:111.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/57\" class=\"nounderline abstract_t\">Jabre P, Combes X, Lapostolle F, et al. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet 2009; 374:293.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/58\" class=\"nounderline abstract_t\">Schenarts CL, Burton JH, Riker RR. Adrenocortical dysfunction following etomidate induction in emergency department patients. Acad Emerg Med 2001; 8:1.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/59\" class=\"nounderline abstract_t\">Bruder EA, Ball IM, Ridi S, et al. Single induction dose of etomidate versus other induction agents for endotracheal intubation in critically ill patients. Cochrane Database Syst Rev 2015; 1:CD010225.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/60\" class=\"nounderline abstract_t\">Absalom A, Pledger D, Kong A. Adrenocortical function in critically ill patients 24 h after a single dose of etomidate. Anaesthesia 1999; 54:861.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/61\" class=\"nounderline abstract_t\">Komatsu R, You J, Mascha EJ, et al. Anesthetic induction with etomidate, rather than propofol, is associated with increased 30-day mortality and cardiovascular morbidity after noncardiac surgery. Anesth Analg 2013; 117:1329.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/62\" class=\"nounderline abstract_t\">Rivera R, Antognini JF. Perioperative drug therapy in elderly patients. Anesthesiology 2009; 110:1176.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/63\" class=\"nounderline abstract_t\">Landoni G, Bignami E, Oliviero F, Zangrillo A. Halogenated anaesthetics and cardiac protection in cardiac and non-cardiac anaesthesia. Ann Card Anaesth 2009; 12:4.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/64\" class=\"nounderline abstract_t\">Raphael J. Physiology and pharmacology of myocardial preconditioning. Semin Cardiothorac Vasc Anesth 2010; 14:54.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/65\" class=\"nounderline abstract_t\">Agarwal B, Stowe DF, Dash RK, et al. Mitochondrial targets for volatile anesthetics against cardiac ischemia-reperfusion injury. Front Physiol 2014; 5:341.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/66\" class=\"nounderline abstract_t\">Uhlig C, Bluth T, Schwarz K, et al. Effects of Volatile Anesthetics on Mortality and Postoperative Pulmonary and Other Complications in Patients Undergoing Surgery: A Systematic Review and Meta-analysis. Anesthesiology 2016; 124:1230.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/67\" class=\"nounderline abstract_t\">Lurati Buse GA, Schumacher P, Seeberger E, et al. Randomized comparison of sevoflurane versus propofol to reduce perioperative myocardial ischemia in patients undergoing noncardiac surgery. Circulation 2012; 126:2696.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/68\" class=\"nounderline abstract_t\">Feringa HH, Vidakovic R, Karagiannis SE, et al. Impaired glucose regulation, elevated glycated haemoglobin and cardiac ischaemic events in vascular surgery patients. Diabet Med 2008; 25:314.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/69\" class=\"nounderline abstract_t\">Noordzij PG, Boersma E, Schreiner F, et al. Increased preoperative glucose levels are associated with perioperative mortality in patients undergoing noncardiac, nonvascular surgery. Eur J Endocrinol 2007; 156:137.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/70\" class=\"nounderline abstract_t\">NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360:1283.</a></li><li><a href=\"https://www.uptodate.com/contents/anesthesia-for-noncardiac-surgery-in-patients-with-ischemic-heart-disease/abstract/71\" class=\"nounderline abstract_t\">Sigmund AE, Fang Y, Chin M, et al. Postoperative Tachycardia: Clinically Meaningful or Benign Consequence of Orthopedic Surgery? Mayo Clin Proc 2017; 92:98.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 90616 Version 26.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H114455937\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H353771159\" id=\"outline-link-H353771159\">INTRODUCTION</a></li><li><a href=\"#H132216151\" id=\"outline-link-H132216151\">PREANESTHESIA CONSULTATION</a><ul><li><a href=\"#H132216315\" id=\"outline-link-H132216315\">Evaluation and management of high cardiac risk</a></li><li><a href=\"#H18794857\" id=\"outline-link-H18794857\">Preoperative medication management</a></li><li><a href=\"#H117881487\" id=\"outline-link-H117881487\">Laboratory</a></li><li><a href=\"#H128997740\" id=\"outline-link-H128997740\">Electrocardiogram</a></li><li><a href=\"#H128998269\" id=\"outline-link-H128998269\">Management of implantable cardioverter defibrillators and pacemakers</a></li></ul></li><li><a href=\"#H132216170\" id=\"outline-link-H132216170\">ANESTHETIC GOALS</a><ul><li><a href=\"#H213850611\" id=\"outline-link-H213850611\">Prevention of ischemia</a></li><li><a href=\"#H295569606\" id=\"outline-link-H295569606\">Monitoring for ischemia</a></li><li><a href=\"#H319624669\" id=\"outline-link-H319624669\">Treatment of ischemia</a></li></ul></li><li><a href=\"#H712337663\" id=\"outline-link-H712337663\">MANAGEMENT OF ANESTHESIA</a><ul><li><a href=\"#H18796184\" id=\"outline-link-H18796184\">Premedication</a></li><li><a href=\"#H18796197\" id=\"outline-link-H18796197\">Selection of anesthetic technique</a></li><li><a href=\"#H132653745\" id=\"outline-link-H132653745\">Local anesthesia with monitored anesthesia care</a></li><li><a href=\"#H114455658\" id=\"outline-link-H114455658\">Neuraxial regional anesthesia</a></li><li><a href=\"#H160717850\" id=\"outline-link-H160717850\">General anesthesia</a><ul><li><a href=\"#H2200606372\" id=\"outline-link-H2200606372\">- Induction</a></li><li><a href=\"#H2200606364\" id=\"outline-link-H2200606364\">- Maintenance</a></li><li><a href=\"#H2200607745\" id=\"outline-link-H2200607745\">- Emergence</a></li></ul></li><li><a href=\"#H31432339\" id=\"outline-link-H31432339\">Management of arrhythmias</a></li><li><a href=\"#H117881860\" id=\"outline-link-H117881860\">Control of glucose</a></li></ul></li><li><a href=\"#H213852252\" id=\"outline-link-H213852252\">POSTOPERATIVE MANAGEMENT</a><ul><li><a href=\"#H213852241\" id=\"outline-link-H213852241\">Monitoring for myocardial injury</a></li><li><a href=\"#H213852141\" id=\"outline-link-H213852141\">Management of pain</a></li></ul></li><li><a href=\"#H1877424708\" id=\"outline-link-H1877424708\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H114455937\" id=\"outline-link-H114455937\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ANEST/90616|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=CARD/96563\" class=\"graphic graphic_algorithm\">- Stepwise approach to perioperative cardiac assessment for CAD</a></li></ul></li><li><div id=\"ANEST/90616|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ANEST/94174\" class=\"graphic graphic_figure\">- Time spent in diastole</a></li></ul></li><li><div id=\"ANEST/90616|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/57075\" class=\"graphic graphic_table\">- Revised cardiac risk index</a></li><li><a href=\"image.htm?imageKey=CARD/57828\" class=\"graphic graphic_table\">- ACC AHA CV risk noncard surgery</a></li><li><a href=\"image.htm?imageKey=ANEST/116645\" class=\"graphic graphic_table\">- Cardiac risk for selected surgical procedures</a></li><li><a href=\"image.htm?imageKey=ANEST/91907\" class=\"graphic graphic_table\">- Factors governing O2 supply and demand in myocardial ischemia</a></li><li><a href=\"image.htm?imageKey=ANEST/96387\" class=\"graphic graphic_table\">- Vasoactive infusions used in the operating room: Adult dosing</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=advanced-cardiac-life-support-acls-in-adults\" class=\"medical medical_review\">Advanced cardiac life support (ACLS) in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-noncardiac-surgery-in-patients-with-heart-failure\" class=\"medical medical_review\">Anesthesia for noncardiac surgery in patients with heart failure</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-open-abdominal-aortic-surgery\" class=\"medical medical_review\">Anesthesia for open abdominal aortic surgery</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-open-pulmonary-resection\" class=\"medical medical_review\">Anesthesia for open pulmonary resection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-the-older-adult\" class=\"medical medical_review\">Anesthesia for the older adult</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=atrial-fibrillation-cardioversion-to-sinus-rhythm\" class=\"medical medical_review\">Atrial fibrillation: Cardioversion to sinus rhythm</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cox-2-selective-inhibitors-adverse-cardiovascular-effects\" class=\"medical medical_review\">COX-2 selective inhibitors: Adverse cardiovascular effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=carotid-endarterectomy\" class=\"medical medical_review\">Carotid endarterectomy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=causes-of-primary-adrenal-insufficiency-addisons-disease\" class=\"medical medical_review\">Causes of primary adrenal insufficiency (Addison's disease)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=congenital-and-acquired-disorders-of-platelet-function\" class=\"medical medical_review\">Congenital and acquired disorders of platelet function</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=control-of-ventricular-rate-in-atrial-fibrillation-pharmacologic-therapy\" class=\"medical medical_review\">Control of ventricular rate in atrial fibrillation: Pharmacologic therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-of-cardiac-risk-prior-to-noncardiac-surgery\" class=\"medical medical_review\">Evaluation of cardiac risk prior to noncardiac surgery</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=general-anesthesia-intravenous-induction-agents\" class=\"medical medical_review\">General anesthesia: Intravenous induction agents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=glycemic-control-and-intensive-insulin-therapy-in-critical-illness\" class=\"medical medical_review\">Glycemic control and intensive insulin therapy in critical illness</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=indications-and-hemoglobin-thresholds-for-red-blood-cell-transfusion-in-the-adult\" class=\"medical medical_review\">Indications and hemoglobin thresholds for red blood cell transfusion in the adult</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=induction-agents-for-rapid-sequence-intubation-in-adults-outside-the-operating-room\" class=\"medical medical_review\">Induction agents for rapid sequence intubation in adults outside the operating room</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=intraoperative-fluid-management\" class=\"medical medical_review\">Intraoperative fluid management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=intraoperative-rescue-transesophageal-echocardiography-tee\" class=\"medical medical_review\">Intraoperative rescue transesophageal echocardiography (TEE)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=intraoperative-transesophageal-echocardiography-for-noncardiac-surgery\" class=\"medical medical_review\">Intraoperative transesophageal echocardiography for noncardiac surgery</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-acute-perioperative-pain\" class=\"medical medical_review\">Management of acute perioperative pain</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-cardiac-risk-for-noncardiac-surgery\" class=\"medical medical_review\">Management of cardiac risk for noncardiac surgery</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=medical-therapy-to-prevent-complications-after-coronary-artery-bypass-graft-surgery\" class=\"medical medical_review\">Medical therapy to prevent complications after coronary artery bypass graft surgery</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neuraxial-anesthesia-analgesia-techniques-in-the-patient-receiving-anticoagulant-or-antiplatelet-medication\" class=\"medical medical_review\">Neuraxial anesthesia/analgesia techniques in the patient receiving anticoagulant or antiplatelet medication</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=noncardiac-surgery-after-percutaneous-coronary-intervention\" class=\"medical medical_review\">Noncardiac surgery after percutaneous coronary intervention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nonselective-nsaids-adverse-cardiovascular-effects\" class=\"medical medical_review\">Nonselective NSAIDs: Adverse cardiovascular effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pacing-system-malfunction-evaluation-and-management\" class=\"medical medical_review\">Pacing system malfunction: Evaluation and management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=perioperative-management-of-heart-failure-in-patients-undergoing-noncardiac-surgery\" class=\"medical medical_review\">Perioperative management of heart failure in patients undergoing noncardiac surgery</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=perioperative-management-of-patients-with-a-pacemaker-or-implantable-cardioverter-defibrillator\" class=\"medical medical_review\">Perioperative management of patients with a pacemaker or implantable cardioverter-defibrillator</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=perioperative-medication-management\" class=\"medical medical_review\">Perioperative medication management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=perioperative-myocardial-infarction-or-injury-after-noncardiac-surgery\" class=\"medical medical_review\">Perioperative myocardial infarction or injury after noncardiac surgery</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=preanesthesia-evaluation-for-noncardiac-surgery\" class=\"medical medical_review\">Preanesthesia evaluation for noncardiac surgery</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-of-embolization-prior-to-and-after-restoration-of-sinus-rhythm-in-atrial-fibrillation\" class=\"medical medical_review\">Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pulmonary-artery-catheterization-indications-contraindications-and-complications-in-adults\" class=\"medical medical_review\">Pulmonary artery catheterization: Indications, contraindications, and complications in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-perioperative-cardiovascular-evaluation-and-management\" class=\"medical medical_society_guidelines\">Society guideline links: Perioperative cardiovascular evaluation and management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-chronic-limb-threatening-ischemia\" class=\"medical medical_review\">Treatment of chronic limb-threatening ischemia</a></li></ul></div></div>","javascript":null}